CDK4 and breast cancer: Using HR<sup>+</sup>/HER2<sup>-</sup> BC models with acquired resistance to the CDK4/6 inhibitors Palbociclib or Ribociclib, we uncovered a metabolic vulnerability in highly resistant clones, mediated by mTORC1 hyperactivation and autophagy suppression.